Charles River Laboratories International Inc. (CRL): Price and Financial Metrics

Charles River Laboratories International Inc. (CRL): $269.37

3.93 (+1.48%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

CRL Price/Volume Stats

Current price $269.37 52-week high $275.00
Prev. close $265.44 52-week low $161.65
Day low $266.06 Volume 288,800
Day high $269.95 Avg. volume 568,410
50-day MA $242.08 Dividend yield N/A
200-day MA $212.62 Market Cap 13.82B

CRL Stock Price Chart Interactive Chart >

CRL POWR Grades

  • CRL scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.08% of US stocks.
  • CRL's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • CRL's current lowest rank is in the Growth metric (where it is better than 25.48% of US stocks).

CRL Stock Summary

  • CRL has a market capitalization of $11,491,510,032 -- more than approximately 84.33% of US stocks.
  • Over the past twelve months, CRL has reported earnings growth of 31.36%, putting it ahead of 76.19% of US stocks in our set.
  • The volatility of CHARLES RIVER LABORATORIES INTERNATIONAL INC's share price is greater than that of merely 16.53% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CHARLES RIVER LABORATORIES INTERNATIONAL INC are WMS, THO, WLK, HLIO, and PLXS.
  • CRL's SEC filings can be seen here. And to visit CHARLES RIVER LABORATORIES INTERNATIONAL INC's official web site, go to www.criver.com.

CRL Valuation Summary

  • CRL's price/sales ratio is 2.9; this is 30.95% lower than that of the median Healthcare stock.
  • Over the past 243 months, CRL's price/sales ratio has gone up 0.3.

Below are key valuation metrics over time for CRL.

Stock Date P/S P/B P/E EV/EBIT
CRL 2023-12-29 2.9 3.7 25.5 19.8
CRL 2023-12-28 2.9 3.7 25.8 20.0
CRL 2023-12-27 2.9 3.7 25.8 20.0
CRL 2023-12-26 2.9 3.7 25.7 20.0
CRL 2023-12-22 2.9 3.7 25.5 19.8
CRL 2023-12-21 2.9 3.7 25.5 19.8

CRL Growth Metrics

    The year over year revenue growth rate now stands at 19.34%.
  • The 4 year cash and equivalents growth rate now stands at 183.17%.
  • The 3 year price growth rate now stands at 91.8%.
CRL's revenue has moved up $1,252,344,000 over the prior 34 months.

The table below shows CRL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 3,976.06 619.64 486.226
2022-09-30 3,781.267 614.141 436.394
2022-06-30 3,688.047 656.084 443.347
2022-03-31 3,629.523 693.2 422.474
2021-12-31 3,540.16 760.799 390.982
2021-09-30 3,426.1 669.92 396.595

CRL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRL has a Quality Grade of C, ranking ahead of 58.62% of graded US stocks.
  • CRL's asset turnover comes in at 0.564 -- ranking 280th of 561 Business Services stocks.
  • CRTO, OOMA, and SCWX are the stocks whose asset turnover ratios are most correlated with CRL.

The table below shows CRL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-26 0.564 0.379 0.141
2021-03-27 0.559 0.371 0.139
2020-12-26 0.553 0.367 0.135
2020-09-26 0.555 0.367 0.119
2020-06-27 0.558 0.361 0.101
2020-03-28 0.570 0.367 0.096

CRL Price Target

For more insight on analysts targets of CRL, see our CRL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $448.00 Average Broker Recommendation 1.35 (Strong Buy)

Charles River Laboratories International Inc. (CRL) Company Bio


Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratorygene therapy and cell therapy services for the PharmaceuticalMedical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry (for example, contract research organization services) and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing. (Source:Wikipedia)


CRL Latest News Stream


Event/Time News Detail
Loading, please wait...

CRL Latest Social Stream


Loading social stream, please wait...

View Full CRL Social Stream

Latest CRL News From Around the Web

Below are the latest news stories about CHARLES RIVER LABORATORIES INTERNATIONAL INC that investors may wish to consider to help them evaluate CRL as an investment opportunity.

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

Charles River Laboratories International, Inc. ( NYSE:CRL ) led the NYSE gainers with a relatively large price hike in...

Yahoo | December 27, 2023

Charles River's (CRL) Memphis Site Achieves Crucial Approval

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.

Yahoo | December 19, 2023

Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration

WILMINGTON, Mass. & MEMPHIS, Tenn., December 18, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]). CASGEVY is approved in some countries for certain eligible patients.

Yahoo | December 18, 2023

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Yahoo | December 13, 2023

Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening

WILMINGTON, Mass. & BERLIN, December 12, 2023--Charles River expands portfolio of 3D in vitro testing services for oncology research with CELLphenomics' proprietary PD3D tumor model platform.

Yahoo | December 12, 2023

Read More 'CRL' Stories Here

CRL Price Returns

1-mo 6.49%
3-mo 13.95%
6-mo 37.45%
1-year 36.33%
3-year -4.80%
5-year 85.45%
YTD 13.95%
2023 8.49%
2022 -42.17%
2021 50.80%
2020 63.56%
2019 34.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!